The global stem cell therapy market is projected to reach USD 31.41 billion by 2030, growing at a CAGR of 13.73% during the forecast period from 2023 to 2030. The market size was estimated at USD 11.22 billion in 2022 and is expected to expand to USD 24.29 billion by 2028. Factors driving the growth of the market include accelerated funding for stem cell therapies, rising interest in stem cell-based therapeutics among investors, increased awareness of promising solutions for severe disorders with the use of stem cell therapies, and advancements in stem cell isolation, expansion, and differentiation techniques. The adult stem cells segment is expected to have the largest share over the forecast period due to increasing use in regenerative medicines, while North America accounted for the largest region in the market in 2022 due to its advanced healthcare infrastructure and favorable policies. The COVID-19 pandemic has also led researchers to explore new treatments using stem cell therapy against SARS-CoV-2 virus. Key players in the market include Athersys Inc., Mesoblast Ltd., Cellular Biomedicine Group, Gamida Cell, Creative Medical Technology Holdings Inc., Smith & Nephew, NuVasive Inc., Pharmicell Inc